证券代码：603222 证券简称：济民健康 公告编号：2025-041 济民健康管理股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 济民健康管理股份有限公司（以下简称"公司"）股票于 2025 年 8 月 22 日、 8 月 25 日、8 月 26 日连续三个交易日内收盘价格跌幅偏离值累计达到 20%，根据 《上海证券交易所交易规则》的相关规定，属于股票交易异常波动。 二、公司关注并核实的相关情况 ●公司股票交易于2025年8月22日、8月25日、8月26日连续三个交易日内收盘 价格跌幅偏离值累计超过20%，属于《上海证券交易所交易规则》规定的股票交易 异常波动情形。 ●经公司自查并书面征询控股股东及实际控制人，截至本公告披露日，公司 不存在应披露而未披露的重大事项。 ●公司敬请广大投资者注意二级市场交易风险、经营业绩风险，敬请广大投 资者理性决策，审慎投资。 一、股票交易异常波动的具体情况 针对股票交易异常波动情况，公司对有关事项进行了核查，现将有关情况说 明如 ...

济民健康(603222)今日下跌7.68%，全天换手率19.33%，成交额9.45亿元，振幅6.25%。龙虎榜数据显 示，营业部席位合计净卖出1778.77万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-7.30%上榜，营业部席位合计净卖出1778.77万元。 济民健康8月26日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 广发证券股份有限公司南京汉中路证券营业部 | 3164.12 | | | 买二 | 国泰海通证券股份有限公司总部 | 981.70 | | | 买三 | 中国银河证券股份有限公司烟台证券营业部 | 876.64 | | | 买四 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 868.13 | | | 买五 | 首创证券股份有限公司长沙滨江路证券营业部 | 836.40 | | | 卖一 | 浙商证券股份有限公司杭州五星路证券营业部 | | 2267.34 | | 卖二 | 中信证券股份有限公司浙江分公司 | 1929.66 | | - ...

Group 1: Company Performance - CanSino reported a revenue of 382 million yuan for the first half of 2025, a year-on-year increase of 26%, with a net loss of 13.49 million yuan, narrowing by 94.02% compared to a loss of 225 million yuan in the same period last year [1] - Wantai Bio disclosed a revenue of 844 million yuan, a year-on-year decrease of 38.25%, resulting in a net loss of 144 million yuan, indicating a shift from profit to loss due to market adjustments and government procurement impacts [2] - Jimin Health reported a revenue of 366 million yuan, a year-on-year decline of 21.30%, with a net loss of 52.70 million yuan, compared to a profit of 25.44 million yuan in the previous year [3] - ST Noratech achieved a revenue of approximately 1.048 billion yuan, a year-on-year increase of 26.07%, with a net profit of about 310 million yuan, reflecting a growth of 36.49% [5] Group 2: Market Trends and Insights - The vaccine industry is facing challenges such as intensified competition and insufficient demand, leading to performance pressure on several companies, including CanSino and Zhifei Biological [2] - Jimin Health's stock experienced a significant increase of 53.78% over a short period, indicating potential market overreaction and speculative trading [3][4] - The demand for peptide raw materials, particularly GLP-1 related products, has driven ST Noratech's performance, highlighting a strong market for specific pharmaceutical segments [5] Group 3: Shareholder Actions - TBP 3Doctors (HK) Limited plans to reduce its stake in Sanbo Brain Science by up to 6.09 million shares, representing 3% of the total share capital, which may signal a lack of confidence in the company's future prospects [6]

Group 1: 康希诺 (CanSino) - The company reported a revenue of 382 million yuan for the first half of 2025, a year-on-year increase of 26% [1] - The net profit attributable to shareholders was a loss of 13.49 million yuan, significantly narrowing from a loss of 225 million yuan in the same period last year, a reduction of 94.02% [1] - Sales revenue from two types of combined meningococcal vaccines reached approximately 364 million yuan, up 38.43% year-on-year [1] Group 2: 万泰生物 (Wantai Bio) - The company reported a revenue of 844 million yuan for the first half of 2025, a year-on-year decrease of 38.25% [2] - The net profit attributable to shareholders turned into a loss of 144 million yuan, compared to a profit in the same period last year [2] - The revenue decline was attributed to market adjustments, government procurement, and the expansion of the nine-valent HPV vaccine age group, leading to lower-than-expected sales [2] Group 3: 济民健康 (Jimin Health) - The company reported a revenue of 366 million yuan for the first half of 2025, a year-on-year decrease of 21.30% [3] - The net profit was a loss of approximately 52.70 million yuan, compared to a profit of 25.44 million yuan in the same period last year [3] - The stock price saw a cumulative increase of 53.78% from August 13 to August 19, with a trading halt on August 20, indicating potential market overreaction [3] Group 4: ST诺泰 (ST Novartis) - The company reported a revenue of approximately 1.048 billion yuan for the first half of 2025, a year-on-year increase of 26.07% [4] - The net profit attributable to shareholders was approximately 310 million yuan, an increase of 36.49% year-on-year [4] - The revenue growth was primarily driven by significant sales increases in peptide raw materials, particularly GLP-1 related products [4] Group 5: 三博脑科 (Sanbo Brain Science) - The shareholder TBP3Doctors (HK) Limited plans to reduce its holdings by up to approximately 6.09 million shares, accounting for 3% of the total share capital [5] - The reduction will occur through centralized bidding and block trading within three months after the announcement [5] - The shareholder's decision to reduce holdings may signal a lack of confidence in the company's future development prospects [5]

Group 1 - The innovative drug concept stocks are experiencing a downturn, with multiple companies such as Guangshengtang, Yuandong Biological, Yangguang Nuohuo, Haitai Biological, Rejing Biological, Kailaiying, Lifang Pharmaceutical, and Jimin Health seeing declines of over 5% [1]

证券代码：603222 证券简称：济民健康 公告编号：2025-040 济民健康管理股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●双鸽集团持有公司股份数量为 127,983,520 股，占公司总股本的 24.37%； 本次股份质押后,双鸽集团质押公司股份 94,140,000 股，占其所持股份总数的 73.56%，占公司总股本的 17.93%。 ●截止本公告日，双鸽集团及其一致行动人合计持有公司股份 233,792,540 股，占公司总股本的 44.52%。本次股份质押后，控股股东累计质押股份 158,540,000 股，占其所持股份的 67.81%，占公司总股本的 30.19%。 一、本次股份质押情况 济民健康管理股份有限公司(以下简称"公司")于 2025 年 8 月 25 日接到双 鸽集团有限公司（以下简称"双鸽集团"）的通知，获悉其将所持有公司的部分 股份质押给浙商银行股份有限公司台州分行（以下简称"浙商银行台州分行"）， 具体情况如下： | | 是否 ...

2025年8月25日，济民健康管理股份有限公司公告称，控股股东双鸽集团于8月20日将4500万股公司股份 质押给浙商银行台州分行，占其所持股份35.16%，占总股本8.57%，用途为补充质押。截至公告日，双 鸽集团及其一致行动人合计持股占总股本44.52%，累计质押股份占其所持股份67.81%，占总股本 30.19%。 本文源自：金融界 ...

Market Overview - On August 22, major A-share indices rose collectively, with the Shanghai Composite Index surpassing 3,800 points, reaching a ten-year high [1] - The total trading volume for the day was 2.58 trillion yuan, an increase of 118.5 billion yuan compared to the previous trading day, marking the eighth consecutive day of trading volume exceeding 2 trillion yuan, setting a historical record for A-shares [1] - Over 2,800 stocks in the market experienced gains [1] Sector Performance - The AI chip, semiconductor, and storage chip sectors saw significant growth, with the multi-modal AI sector and CPO concept being particularly active [1] - Conversely, the gas and shale gas sectors declined, with ecological agriculture, fertilizer, dairy, and banking sectors experiencing the largest drops [1] Top Stocks on the Dragon and Tiger List - The top net buying stocks included Heertai, Haiguang Information, and Chuanrun Shares, with net purchases of 859 million yuan, 449 million yuan, and 359 million yuan respectively [3] - The top net selling stocks were Cambricon, Jishi Media, and Jimin Health, with net sales of 678 million yuan, 204 million yuan, and 156 million yuan respectively [3] Notable Stock Movements - Heertai saw a price increase of 10.02% with a trading volume of 62.38 billion yuan and a turnover rate of 21.72% [4] - Haiguang Information surged by 20.00% with a trading volume of 133.10 billion yuan and a turnover rate of 3.23% [4] - Chuanrun Shares increased by 10.03% with a trading volume of 22.82 billion yuan and a turnover rate of 33.06% [4] Company Financials - Jishi Media reported a revenue of 999.7 million yuan for the first half of 2025, a year-on-year increase of 8.70%, but incurred a net loss of 232 million yuan, a decline of 18.82% [11] - Jimin Health achieved a revenue of 366 million yuan in the first half of the year, a year-on-year decrease of 21.30%, and reported a net loss of 52.7 million yuan [14]

济民健康(603222)今日跌停，全天换手率23.31%，成交额13.04亿元，振幅11.11%。龙虎榜数据显示， 营业部席位合计净卖出1.56亿元。 具体来看，今日上榜营业部中，第一大买入营业部为国泰海通证券股份有限公司总部，买入金额为 5185.13万元，第一大卖出营业部为东方证券股份有限公司杭州龙井路证券营业部，卖出金额为1.17亿 元。 近半年该股累计上榜龙虎榜7次，上榜次日股价平均涨2.08%，上榜后5日平均涨5.15%。 资金流向方面，今日该股主力资金净流出2.02亿元，其中，特大单净流出2.00亿元，大单资金净流出 146.25万元。近5日主力资金净流出1.76亿元。 融资融券数据显示，该股最新（8月21日）两融余额为2.93亿元，其中，融资余额为2.93亿元，融券余额 为10.15万元。近5日融资余额合计增加1.25亿元，增幅为73.95%。融券余额合计增加9.34万元，增幅 1152.59%。 8月21日公司发布的半年报数据显示，上半年公司共实现营业收入3.66亿元，同比下降21.30%，实现净 利润-5269.59万元。（数据宝） 济民健康8月22日交易公开信息 | 买/ | 会员营业部名 ...

格隆汇8月22日｜此前连续5日涨停的济民健康（维权）(603222.SH)连续2日回调，午间收跌7.11%报10.59元，总市值55.6亿元。消息上，济民健康日前公 告，2025年上半年营业收入3.66亿元，同比下降21.30%。净利润亏损5269.59万元，上年同期净利润2544.5万元。报告期，公司不进行利润分配及资本公积转 增股本。日前该股持续上涨，公司多次公告提示"非理性炒作"，表明短期上涨缺乏基本面支撑。(格隆汇) ...